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Summary. A novel natural peptide ergot alkaloid -ergokryptinine con-
taining norleucine has been isolated from ergot sclerotia of the field-
growing parasitic fungus Claviceps purpurea CCM 8059. Its structure
was deduced from the NMR and mass spectral data. The final structural
proof was provided by the crystal structure determination, which is the
first X-ray structure of a natural Nle-containing secondary metabolite. The
conformations of three ergopeptinines: -ergokryptinine, ergoladinine, and
-ergokryptinine were compared.
Keywords: Norleucine – Ergot alkaloids – -Ergokryptinine – Crystal
structure determination
1 Introduction
It seemed until recently that the number of ergot alkaloids
of peptidic type is limited to 12 by a combination of 3
amino acids (Ala, -Abu, and Val) at the first and 4 amino
acids (Val, Phe, Leu, Ile) at the second position of the
tripeptide moiety of ergopeptines (Stadler, 1982; Buchta
and Cvak, 1999). From the historical point of view, the
forgotten ergoheptine, which was described based on the
paper chromatography only (Abe et al., 1970; P€ohm,
1954), was probably the later identified -ergokryptine
(Schlientz et al., 1967). During the last two decades of
20th century several new alkaloids have been prepared by
directed biosynthesis (Beacco et al., 1978; Baumert, 1982;
Flieger et al., 1984; Crespi-Perellino et al., 1992), but only
a few of new ergopeptines were found in nature with the
genus Claviceps (Bianchi et al., 1982; Crespi-Perellino
et al., 1993; Powell et al., 1990; Cvak et al., 1994; Szántay
et al., 1994; Cvak et al., 1996; Halada et al., 1998), other
fungal genera, e.g., Acremonium (Yates et al., 1985),
Sphacelia (Atwell and Mantle, 1981), Dicyma (Vázquez
et al., 2003), and in higher plants (Jenett-Siems et al.,
1994). Analyses of amino acids in hydrolysates of scle-
rotia of the parasitic fungus Claviceps purpurea and of
crude alkaloid mixtures have revealed the presence of
some additional aliphatic amino acids and led to the pre-
diction of the existence of yet unknown natural ergot
alkaloids (Jegorov et al., 1997). Here we report the iden-
tification and crystal structure determination of a novel
alkaloid named -ergokryptinine (Fig. 1).
2 Material and methods
2.1 Instruments and methods
NMR spectra were measured on a Varian Inova-400 (399.88 MHz for 1H,
100.55 MHz for 13C, CDCl3, 30
C). Following experiments have been
performed: H, C, HOM2DJ, gCOSY, TOCSY, HMQC, gHMQC, 1D-
TOCSY. Chemical shifts are reported in -scale. Positive-ion ESI spectra
were recorded on a Finnigan LCQ ion trap instrument (Finnigan MAT,
Bremen, Germany). IR spectrum was measured on Nicolet Nexus in KBr
pellet and UV spectrum was recorded on Varian DMS 300 in acetonitrile.
2.2 Isolation of -ergokryptinine
Crude -ergokryptine (70.0 kg) was dissolved in the mixture of toluene
(270 l) and of methanol (70 l) and the solution was concentrated to the
volume of about 150 l in vacuum and diluted by toluene (150 l). The crys-
talline -ergokryptine was filtered off and washed by toluene. The mother
liquors were concentrated to dryness and the residue was dissolved in
methanol (8 l) and the solution was refluxed for 4 hours. The obtained
crystalline product was filtered off and washed with methanol, giving a
mixture of ergopeptinines (1620 g). According to the HPLC analysis, the
mixture consisted of -ergokryptinine (85.4%), ergogalinine (3.7%), ergo-
cristinine (2.1%), ergocorninine (2.4%), ergoladinine (1.3%), an unknown
alkaloid (1.5%), identified later as -ergokryptinine, and some other
unknown alkaloids. The mixture of ergopeptinines (500 g) was chromato-
graphed on 10 weight parts of silica gel (Merck, 60 A, 63–200m) using
dichloromethane with 0.5% methanol as eluent. The fraction containing
the unknown alkaloid was chromatographed twice more using the same
chromatographic system, giving a concentrate (0.80 g) which was crystal-
lised from methanol, affording the mixture (0.55 g) of -ergokryptinine
(59.4%) and -ergokryptinine (35.0%).
The -ergokryptinine concentrate (0.50 g) was purified by prepara-
tive HPLC on modified silica containing bonded aminopropyl groups
(Column Separon SGX NH2, 250 25 mm, I.D., 5m, from Watrex,
Fig. 1. Numbering scheme for NMR spectrum of -ergokryptinine
Table 1. 1H and 13C NMR data of -ergokryptinine (399.88 and 100.55 MHz, CDCl3, 30
C)
Atom C m. H nH m. J [Hz] HMBC (C to H)
2 118.37 D 6.908 1 dd 1.9, 1.8 NH, 4e, 4a
3 110.02 S – 0 NH, 2, 4e, 4a
4 27.56 T 3.598 1 dd 14.3, 5.4 5
2.676 1 ddd 14.3, 11.5, 1.8
5 62.84 D 3.239 1 dddd 11.5, 5.4, 2.2, 2.1 4e, 4a, 7e, 7a, 9, NMe
7 54.73 T 3.161 1 ddd 11.9, 1.3, 1.2 9, NMe
2.764 1 dd 11.9, 3.7
8 44.01 D 3.087 1 m 7e, 9
9 117.61 D 6.521 1 ddd 6.4, 2.1, 1.2 5, 7e, 8
10 137.29 S – 0 4e, 4a, 5, 8, 12
11 127.41 S – 0 9a, 13
12 112.84 D 7.114 1 dd 7.2, 1.1 14
13 123.40 D 7.155 1 dd 7.7, 7.1
14 110.16 D 7.220 1 dd 7.7, 1.1 12
15 133.95 S – 0 NH, 2, 13
16 126.25 S – 0 NH, 2, 4e, 4a, 12, 14
17 176.26 S – 0 7a, 7e, 8, 9, CONH
NH – – 8.149 1 d 1.9
NMe 43.36 Q 2.629 3 s 5, 7e
CONH – – 9.949 1 s
10 165.37 S – 0 CONH
10 89.94 S – 0 10, 10d, 1
0u, CONH
10 34.18 D 2.080 1 qq 6.9, 6.8 10d, 1
0u,CONH
10d 15.53 Q 1.147 3 d 6.9 1
0, 10u
10u 17.00 Q 0.920 3 d 6.8 1
0, 10d
20 165.86 S – 0 20
20 55.13 D 4.380 1 dd 7.0, 5.8 20d, 2
0u, ,2
0u













20" 13.95 Q 0.880 3 t 7.3 20
30 103.48 S – 0 20, 30, 30–OH
30 64.35 D 3.654 1 ddd 10.0, 6.2, 1.8 30d, 3
0u, 3
0–OH









30 45.95 T 3.618 1 m 30d, 3
0u
3.540 1 m
30–OH – – 7.329 1 d 1.8
a axial; e equatorial; d downfield; u upfield
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Czech Republic, isocratic elution with the dichloromethane=methanol
99:1 v=v mixture, flow 7 ml=min, detector set at 345 nm). Fractions were
pooled according the analytical results of individual fractions (Column
Separon SGX NH2, 250 4 mm, I.D., 5m, from Tessek, Czech Republic,
isocratic elution with the dichloromethane=methanol 99:1 v=v mixture, flow
2.5 ml=min, detector set at 310 nm, relative retention time of -ergokrypti-
nine was 1.22 with respect to-ergokryptinine). Finally, about 100 mg of -
ergokryptinine of purity>99% was isolated. Single crystals were prepared
by dissolution of -ergokryptinine (23 mg) in methanol (3.5 ml) at 64C,
subsequent addition of water (100l), and standing overnight. Mp.
238.8–239.6C (microscope, between cover plates). IR (KBr pellet): O–H
stretching 3309 m, C¼O stretching 1665 s, 1645 s, and 1729 s, C¼C stretch-
ing 1564 w, 1604 w [cm1]. UV (acetonitrile): 311 nm ("M ¼ 6.3 
103 dm3 mol1 cm1), 241 nm ("M ¼ 1.6  104 dm3 mol1 cm1).
2.3 Crystallographic study
-Ergokryptinine C32H41N5O5, Mr¼ 575.71, orthorhombic, space
group P212121, a¼ 6.5600(1), b¼ 17.8830(3), c¼ 25.4550(4) Å, V¼
2986.19(8) Å3, Z¼ 4, Dc¼ 1.280 g cm3, Nonius Kappa CCD area-detector
diffractometer, ’ and ! scans technique, MoK radiation, ¼ 0.71073 Å,
T¼ 150(2) K. A total of 51419 reflections were measured (h 8! 8,
k 23! 23, l 32! 33, max¼ 27.48). Merging equivalents gave 5401
unique reflections (Rint¼ 0.07), of which 3034 were unique and observed
(I>1.96 (I)) and used for the refinement. The structure was solved by
direct methods and anisotropically refined. The H-atoms were placed in
their calculated positions and allowed to ride on their attached C-atoms
in distances of 1.0 Å. The atoms H511, H531 and H551 were located
in difference Fourier maps and refined fixed. The minimized function
was Sw(FoFc)2 , where w¼ [weight][1 (F=6F)2]2, (Prince, 1982;
Watkin, 1994), (=)max¼ 0.0003, R¼ 0.042, S¼ 1.075 with the largest
residual peaks of 0.23 and 0.19 e  Å3. Data collection: COLLECT
(Nonius, 1997); cell refinement: DENZO=SCALEPACK (Otwinowski
and Minor, 1997); data reduction: DENZO=SCALEPACK; program used
to solve structure: SHELXS86 (Sheldrick, 1986); program used to
refine structure: CRYSTALS (Watkin et al., 2001); molecular graphics:
ORTEP-3 (Farrugia, 1997).
Important backbone conformation angles []: Val: ’2¼63.6(3),
 2¼ 112.1(2), !2¼178.3(2), 	21;1 ¼ 176.2(2), 	21;2 ¼59.5(3); Nle:
’3¼147.3(2),  3¼ 2.6(3), !3¼5.1(4), 	31 ¼49.4(3), 	32 ¼
171.3(2), 	33 ¼58.6(3); Pro: ’4¼22.6(3),  4¼ 49.5(2). Full data
are deposited with the Cambridge Crystallographic Data Centre.
-Ergokryptinine (IVAX Pharmaceuticals, crystallised from methanol=
water) C32H41N5O5, Mr¼ 575.71, orthorhombic, space group P212121,
a¼ 6.571(1), b¼ 18.337(4), c¼ 26.234(5) Å, V¼ 3161(1) Å3, Z¼ 4,
Dc¼ 1.210 g cm3, Nonius CAD4 diffractometer, 2=! scans technique,
CuK radiation, ¼ 1.54184 Å, T¼ 293 K. A total of 6283 reflections
were measured (h 0! 8, k 0! 22, l 31! 31, max¼ 69.93), 5130 of
them were unique and observed (I>2 (I)) and included in the structure
analysis. The structure was solved by direct methods and anisotropically
refined. C28 in the valine residue is disordered in two positions labelled as
C28 of occupancy 0.68(1) – conformation denoted as A, and C280, occu-
pancy 0.32(1) – B. The most of the leucine residue is disordered in two
branches – C30, C31 and C32 of occupancy 0.29(2) – A, and C300, C310
and C320 of occupancy 0.71(2) – B. The H-atoms were located in differ-
ence Fourier maps and isotropicaly refined, except of H1, H4, H52, H232,
which were refined riding in distance of 0.95(1) Å and those H-atoms in
disordered residues, that were refined riding in their calculated positions
with their respective occupancy values. The minimized function was
Sw(Fo2Fc2)2, where w¼ 1=[2(Fo2)þ (0.1236P)2þ 1.0004P] and
P¼ (Fo2þ 2Fc2)=3, (=)max¼0.005, R¼ 0.0670, S¼ 1.028 with the
largest residual peaks of 0.18 and 0.74 e  Å3. Data collection, cell
refinement and data reduction: SDP (Frenz, 1985); program used to solve
structure: SHELXS86 (Sheldrick, 1986); program used to refine structure:
SHELXL (Sheldrick, 1993).
Important backbone conformation angles []: conformation of Val:
’2¼47.2(5),  2¼ 112.1(2), !2¼177.8(3), 	21;2 ¼63.0(5), confor-
mation of Val A: 	2
1;1 ¼ 166.6(5), conformation of Val B: 	21;1 ¼ 65(1);
Leu: ’3¼149.5(3),  3¼7.9(5), !3¼ 0.9(6), conformation of Leu A:
	3
1 ¼63(1), 	32;1 ¼58(2), 	32;2 ¼ 179(2); conformation of Leu B:
	3
1 ¼ 157(1), 	32;1 ¼87(1), 	32;2 ¼ 179(2); Pro: ’4¼19.8(5),  4¼
44.5(4). Full data are deposited with the Cambridge Crystallographic
Data Centre.
CCDC contains the supplementary crystallographic data for this paper:
-ergokryptinine CCDC 227875 and -ergokryptinine CCDC 227876.
These data can be obtained free of charge via www.ccdc.cam.ac.uk=
conts=retrieving.html (or from the CCDC, 12 Union Road, Cambridge
CB2 1EZ, UK; fax: þ44 1223 336033; e-mail: deposit@ccdc.cam.ac.uk)
3 Results and discussion
In our program of searching for potential impurities of
ergotoxine, we identified an unusual ergopeptine contain-
ing norleucine. A crude alkaloid concentrate was obtained
by the extraction of an ergot strain producing -ergokryp-
tine (Claviceps purpurea CCM 8059), but was also found
in other ergot strains producing ergotoxine. The concen-
trate of -ergokryptine was crystallised from toluene and
the mother liquors were concentrated and converted to a
mixture of ergopeptinines by crystallisation from metha-
nol. The mixture of ergopeptinines was then separated by
chromatography on a silica gel. Finally, -ergokryptinine
fraction was purified by preparative HPLC and crystal-
lised from methanol=water.
Mass spectrometry revealed that the compound is iso-
baric with- or-ergokryptines (C32H41N5O5). Also the ms
2
of the [MþH]þ ion m=z 576 provided identical fragment
ion [MþHH2O]þ m=z 558 and ion m=z 348, represent-
ing the splitting of the diketopiperazine moiety. The later
ion, analogous to the fragmentation observed under EI con-
ditions (Crespi-Perellino et al., 1987), makes it possible to
calculate the summary composition of the side chains of
the first and second amino acid of the tripeptide moiety as
C3H7 and C4H9, respectively, but lacks the information
about the structure and chirality of these side chains.
The observation of three carbonyls and two sp3-hybrid-
ized carbons attached to two heteroatoms each shows that
the investigated compound belongs to ergot peptide alka-
loids. There are thirty-two signals in the 13C NMR spectrum:
four methyls, eight methylenes, ten methines (four ¼CH
among them), and ten quaternary carbons. Thirty-eight
hydrogens are bonded to carbons; three to heteroatoms
(two N–H’s and one OH, see below). These facts verify
the summary formula C32H41N5O5.
1H NMR spectrum
contains, besides the singlets of N-methyl and CONH, a
three-spin system made of vicinal aromatic protons, and
partial structures (CH3)2CH–, NCH(CH2)3CH3, –NHCH¼
CCH2CHC¼CHCH(X–)CH2–, C(OH)CHN(CH2)3. Indole
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NH, CONH and 30-OH were easily differentiated accord-
ing to their coupling pattern in HMBC (Fig. 2). This
experiment also determines the attachment of CONH to
C-8 (X above) and the location of N-methyl between C5
and C7. Therefore, the molecule contains a 9-ergolene
moiety. To determine the configuration at C8, the confor-
mation of the ring D has to be solved first (Pierri et al.,
1982; Cvak et al., 1994a). Coupling J8,9 ¼ 6.4 Hz means a
pseudoequatorial H8. Chemical shift of CONH proton
corresponds to its participation in hydrogen bonding; that
of H5 (3.239 ppm) is diagnostic for a trans arrangement
of H5 and the nitrogen lone electron pair (Bailey and Grey,
1972). Therefore, the D-ring exists in so-called flap-up
conformation and the cyclol is 8- attached (i.e., indeed
an ‘‘-inine’’). Isolated isopropyl group is attached to C10.
The n-butyl side chain is attached to C20 and the proline
is located in its usual position. Long-range coupling
between H20 and H30 suggest that both these atoms
are located on the same side of the (modified) diketopi-
perazine ring.
The final structural proof was provided by the crystal
structure determination, Fig. 3. The X-ray study has con-
firmed the elemental composition, presence of norleucine
in -ergokryptinine and provided relative configuration
of all its chiral centres. Up to now, only few X-ray
structures of norleucine (Harding et al., 1995) or its
synthetic derivatives (Nigovic et al., 1992; Fenude and
Casalone, 1996) have been reported. Structure of -
ergokryptinine is apparently the first X-ray structure of
natural norleucine-containing secondary metabolite.
The conformation of -ergokryptinine is very close to
that found in ergoladinine structure (Cvak et al., 1996).
The almost isostructural molecular packing explains this
surprisingly high similarity. The analogous force fields of
the neighbours allow molecules to settle in similar con-
formations and vice versa the chemical and sterical
demands of the molecules make the compounds crystal-
lise in the same structural type. For comparison, the
crystal structure of -ergokryptinine was also deter-
mined. Despite some obvious differences in the confor-
mation of the side chain of leucine (see Experimental),
this third structure of ergopeptinines determined so far
indicates that these compounds tend to prefer the same
structural arrangement.
There are two intramolecular hydrogen bonds in the struc-
ture of -ergokryptinine: the obligatory O5-H551 . . .O1
typical for ergopeptine alkaloids and N3-H531 . . .N2,
which stabilises the ‘flap-up’ conformation present in bases
only. The only intermolecular bond is provided by N1-
H511 . . .O4 (xþ 1=2,y,þz 1=2), which forms
infinite chains along the 21 screw axis in Z direction. This
interaction appears to be responsible for the needle-like
shape of the crystals.
Fig. 3. ORTEP drawing of -ergokryptinine, thermal elipsoids are drawn
at 50% probability
Fig. 2. Long range couplings in NMR spectrum of -ergokryptinine
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-Ergokryptinine belongs to the iso-lysergic acid series
(-inines) with the 8 configuration at the C-8 atom. Simi-
larly as with other series of secondary metabolites synthe-
sised extraribosomally by multienzyme system (Keller,
1999), the possibility that norleucine can be incorporated
instead of aliphatic amino acids is not unexpected and has
already been detected by in vitro experiments (Beacco
et al., 1978). Moreover, also the misincorporation of nor-
leucine (amino acid side chain –(CH2)3–CH3) instead of
methionine (–(CH2)2–S–CH3) is well known even with
ordinary protein synthesis (Jakubowski and Goldman,
1992). It is worth mentioning that just methionine con-
taining ergot alkaloid was described recently (Cvak et al.,
1996). Thus, -ergokryptinine is the 8th member of ergo-
toxine (-inine) series (Bianchi et al., 1982; Cvak et al.,
1994b, 1996).
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Pakhomova S, Kratochvı́l B, Granzin J (1994b) Ergogaline, a new
ergot alkaloid, produced by Claviceps purpurea: Isolation, identifica-
tion, crystal structure and molecular conformation. J Chem Soc, Perkin
Trans 2: 1861–1865
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